文献速递肝病消化道肿瘤与早癌

加拿大丙型肝炎患者持续病毒学应答对肝细胞癌的长期影响

Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
PubMed 文献 · J Hepatol · 2016-11-04

基于加拿大不列颠哥伦比亚省1990–2013年检测队列,8147例接受干扰素为基础治疗的患者中57%获得持续病毒学应答(SVR)。SVR组肝细胞癌发生率1.1/1000人年 vs 未SVR组7.2/1000人年;多变量模型SVR与较低肝细胞癌风险相关(SHR=0.20,95%CI 0.13–0.3)。SVR大幅降低但未消除肝细胞癌风险,肝硬化及年龄≥50岁者风险仍高。

要点

  • SVR与较低肝细胞癌风险相关(SHR=0.20,95%CI 0.13–0.3)。
  • SVR组肝细胞癌发生率1.1/1000人年,未SVR组7.2/1000人年。
  • 肝硬化患者SVR后肝细胞癌发生率6.4/1000人年,未SVR者21.0/1000人年。

核心结论

  • 干扰素为基础治疗获得SVR大幅降低但未消除肝细胞癌风险,肝硬化及治疗开始时年龄≥50岁者风险显著更高。
  • 作者认为对晚期纤维化阶段患者使用新型高效药物治疗后,SVR后仍需持续监测肝细胞癌。

研究设计与样本

  • 基于人群的加拿大不列颠哥伦比亚省丙型肝炎检测者队列,纳入1990–2013年检测丙型肝炎病毒者,链接就诊、住院、癌症、处方药和死亡数据。
  • 8147例接受干扰素为基础丙型肝炎治疗并符合分析条件的患者,从治疗结束随访至肝细胞癌诊断、死亡或2012年12月31日。
  • 采用多变量比例风险模型(Fine和Gray竞争风险修正)分析SVR与未SVR者的肝细胞癌风险。

主要发现

  • 8147例中4663例(57%)获得SVR,3484例(43%)未获得SVR;每组中位随访5.6年(范围0.5–12.9年)。
  • 肝细胞癌发生率SVR组为1.1/1000人年,未SVR组为7.2/1000人年。
  • 肝硬化患者肝细胞癌发生率SVR组6.4/1000人年,未SVR组21.0/1000人年。
  • 多变量模型中SVR与较低肝细胞癌风险相关(SHR=0.20,95%CI 0.13–0.3);肝硬化(SHR=2.61,95%CI 1.68–4.04)、年龄≥50岁、男性和基因3型感染与较高肝细胞癌风险相关。
  • SVR获得者中,肝硬化、年龄≥50岁和男性与较高肝细胞癌风险相关。

临床怎么用

  • 作者认为对晚期纤维化阶段患者使用新型高效药物治疗后,SVR后仍需持续监测肝细胞癌。
  • 作者指出肝硬化及治疗开始时年龄≥50岁者SVR后肝细胞癌风险仍显著更高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Evidence is limited on hepatocellular carcinoma (HCC) risk after sustained virological response (SVR) to interferon-based treatment of hepatitis C virus (HCV) infection. We evaluated the effect of SVR on the risk of HCC and estimated its incidence in post-SVR HCV patients from a large population-based Canadian cohort. METHODS: The British Columbia Hepatitis Testers Cohort includes individuals tested for HCV between 1990-2013 linked with data on their medical visits, hospitalizations, cancers, prescription drugs and mortality. Patients receiving interferon-based HCV treatments were followed from the end of treatment to HCC diagnosis, death or December 31, 2012. We examined HCC risk among those who did and did not achieve SVR using multivariable proportional hazard models with the Fine and Gray modification for competing risks. RESULTS: Of 8147 individuals who received HCV treatment and were eligible for analysis, 4663 (57%) achieved SVR and 3484 (43%) did not. Each group was followed for a median of 5.6years (range: 0.5-12.9) for an HCC incidence rate of 1.1/1000 person-years (PY) among the SVR and 7.2/1000 PY among the no SVR group. The HCC incidence rate was higher among those with cirrhosis (SVR: 6.4, no SVR: 21.0/1000 PY). In the multivariable model, SVR was associated with a lower HCC risk (subdistribution hazard ratio [SHR]=0.20, 95% CI: 0.13-0.3), while cirrhosis (SHR=2.61, 95% CI: 1.68-4.04), age ⩾50years, being male and genotype 3 infection were associated with a higher HCC risk. Among those who achieved SVR, cirrhosis, age ⩾50years and being male were associated with a higher HCC risk. CONCLUSION: SVR after interferon-based treatment substantially reduces but does not eliminate HCC risk, which is markedly higher among those with cirrhosis and age ⩾50years at treatment initiation. Treatment of patients at an advanced fibrosis stage with new highly effective drugs will warrant continued surveillance for HCC post-SVR. LAY SUMMARY: We assessed the effect of successful hepatitis C treatment with older interferon-based treatment on the occurrence of liver cancer (hepatocellular carcinoma) and found that successful treatment prevents liver cancer. However, more people with cirrhosis and older age continued to develop liver cancer after successful treatment. Thus, treatment with new drugs among those with cirrhosis will require continued monitoring for liver cancer.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Janjua NZ, Chong M, Kuo M, et al. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada. J Hepatol. 2016. PMID: 27818234. doi:10.1016/j.jhep.2016.10.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。